From:
Columbia Business School’s Linda Green spoke with Newsday about the potential impact of TrumpRx on New Yorkers, particularly in relation to prescription drug pricing and access. Green discussed how changes in pharmaceutical policy can affect patients, insurers, and healthcare providers across the state. Her commentary highlights the broader economic and public health implications of drug pricing reforms.
